Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Effect of GVHD prophylaxis on renal function and survival outcomes in allogeneic hematopoietic cell transplant patients with pre-existing renal impairment

Blood (2025) 146 (Supplement 1): 7764.

https://doi.org/10.1182/blood-2025-7764

Published: 2025

Journal Articles

Outcomes of elderly (≥ 70) Acute Myeloid Leukemia (AML) patients receiving continued hypomethylating agent/venetoclax (HMA/VEN) versus allogeneic hematopoietic cell transplantation (HCT)

Blood (2025) 146 (Supplement 1): 4300.

https://doi.org/10.1182/blood-2025-4300

Published: 2025

Journal Articles

Rare cancer, rare survivors: A 20-year single-center review of adult T-cell lymphoma/leukemia treatment outcomes

Yumeng Zhang, Hayder Saeed, Amin Azem, Jose Sandoval-Sus, Fatima Tuz Zahra, Kavita Ghia, Abu-Sayeef Mirza, Bijal Shah, Celeste Bello, Javier Pinilla-Ibarz, Ling Zhang, Lubomir Sokol

Blood (2025) 146 (Supplement 1): 7161.

https://doi.org/10.1182/blood-2025-7161

Published: 2025

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Fatima Tuz Zahra, Yumeng Zhang, Sameh Gaballa, Celeste Bello, Samuel Reynolds, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Hayder Saeed, Aleksandr Lazaryan, Abu-Sayeef Mirza, Lubomir Sokol, Bijal Shah, Frederick Locke, Michael Jain, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 4555.

https://doi.org/10.1182/blood-2025-4555

Published: 2025

Journal Articles

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Blood (2025) 146 (Supplement 1): 4537.

https://doi.org/10.1182/blood-2025-4537

Published: 2025

Journal Articles

Impact of pre-existing psychiatric conditions on toxicity and outcomes of patients after BCMA-directed CAR-T cell therapy

Blood (2025) 146 (Supplement 1): 6371.

https://doi.org/10.1182/blood-2025-6371

Published: 2025

Journal Articles

Infections in patients with relapsed refractory multiple myeloma receiving idecabtagene vicleucel therapy: A real-world analysis from CIBMTR

Muhammad Bilal Abid, Kitsada Wudhikarn, Qiran Ye, Michael Martens, Abu-Sayeef Mirza, Lohith Gowda, Srinivas Devarakonda, Yvonne Efebera, Zeinab El Boghdadly, Christopher Dandoy, Othman Akhtar, Temitope Oloyede, Christen Ebens, Joshua Hill, Hemant Murthy, Miguel-Angel Perales, Anna Huppler, Jeffery Auletta

Blood (2025) 146 (Supplement 1): 716.

https://doi.org/10.1182/blood-2025-716

Published: 2025

Journal Articles

Refined elderly comorbidity index is highly predictive of post-transplant survival in older adults with Acute Myeloid Leukemia and myelodysplastic syndrome

Blood (2025) 146 (Supplement 1): 6076.

https://doi.org/10.1182/blood-2025-6076

Published: 2025

Journal Articles

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Blood (2025) 146 (Supplement 1): 133.

https://doi.org/10.1182/blood-2025-133

Published: 2025

Journal Articles

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Yumeng Zhang, Fatima Tuz Zahra, Daniel DeAvila, Bijal Shah, Sameh Gaballa, Celeste Bello, Hayder Saeed, Abu-Sayeef Mirza, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Aleksandr Lazaryan, Lubomir Sokol, Frederick Locke, Michael Jain, Zachary Thompson, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 2767.

https://doi.org/10.1182/blood-2025-2767

Published: 2025

Journal Articles

Impact of pre-existing central nervous system conditions and cognitive impairments on toxicity and outcomes after BCMA-directed CAR-T cell therapy

Blood (2025) 146 (Supplement 1): 6370.

https://doi.org/10.1182/blood-2025-6370

Published: 2025

Journal Articles

Impact of autoimmune disease on outcomes after BCMA-directed CAR-T cell therapy for patients with multiple myeloma

Blood (2025) 146 (Supplement 1): 6362.

https://doi.org/10.1182/blood-2025-6362

Published: 2025

Journal Articles

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Blood (2025) 146 (2): 167–177.

https://doi.org/10.1182/blood.2024026216

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of Neurological and Psychiatric Comorbidities on Toxicity and Outcomes of Patients with DLBCL Who Receive Axicabtagene Ciloleucel

Rebecca Albuquerque, Anna Shamis, Athanasios Tsalatsanis, Ambuj Kumar, Zain Ahmad, Hasiq Ovais, Aleksandr Lazaryan, Farhad Khimani, Rawan Faramand, Ciara Louise Freeman, Bijal D Shah, Sameh Gaballa, Julio C. Chavez, Fabiana Perna, Jose L. Ochoa-Bayona, Frederick L. Locke, Michael D. Jain, Taiga Nishihori, Abu-Sayeef Mirza

Blood (2024) 144 (Supplement 1): 7734.

https://doi.org/10.1182/blood-2024-208905

Published: 2024

Journal Articles

Impact of Autoimmune Disease on Toxicity and Outcomes after Axicabtagene Ciloleucel in Patients with Diffuse Large B Cell Lymphoma

Anna Shamis, Rebecca Albuquerque, Athanasios Tsalatsanis, Ambuj Kumar, Zain Ahmad, Hasiq Ovais, Aleksandr Lazaryan, Farhad Khimani, Rawan Faramand, Ciara Louise Freeman, Bijal D Shah, Sameh Gaballa, Julio C. Chavez, Fabiana Perna, Jose L. Ochoa-Bayona, Frederick Locke, Michael D. Jain, Taiga Nishihori, Abu-Sayeef Mirza

Blood (2024) 144 (Supplement 1): 7733.

https://doi.org/10.1182/blood-2024-208743

Published: 2024

Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood (2024) 143 (26): 2722–2734.

https://doi.org/10.1182/blood.2023023447

Published: 2024

Includes: Supplemental data

Journal Articles

CD25 As Feedback Regulator of Oncogenic TCR Signaling in T-Cell Lymphoma

Ruifeng Sun, Jaewoong Lee, Tim Wartewig, Mark E. Robinson, Alberto Bigogno, David Fonseca Arce, Abu-Sayeef Mirza, Andrew Takeda, Lars Klemm, Vivasvan Vykunta, Brian Shy, Alexander Marson, Markus Müschen

Blood (2022) 140 (Supplement 1): 5975–5976.

https://doi.org/10.1182/blood-2022-170076

Published: 2022

Journal Articles

Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)

Abu-Sayeef Mirza, Chitra Hosing, Francine M. Foss, Soyoung Kim, Amy Moskop, Temitope Oloyede, Sairah Ahmed, Peiman Hematti, Cameron J. Turtle, Marcelo C. Pasquini, Lohith Gowda

Blood (2022) 140 (Supplement 1): 4633–4635.

https://doi.org/10.1182/blood-2022-163750

Published: 2022

Journal Articles

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Abu-Sayeef Mirza, Alexander Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean Gu, Yuxin Liu, Jennifer VanOudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian

Blood (2022) 140 (Supplement 1): 10410–10412.

https://doi.org/10.1182/blood-2022-168374

Published: 2022

Journal Articles

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

Frederick L. Locke, Caron Jacobson, Long Ma, Hua Dong, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David B. Miklos, Yi Lin, Miguel-Angel Perales, Matthew A. Lunning, Megan M. Herr, Brian T. Hill, Siddhartha Ganguly, Abu-Sayeef Mirza, Sarah Nikiforow, Hairong Xu, Marcelo C Pasquini

Blood (2021) 138 (Supplement 1): 530.

https://doi.org/10.1182/blood-2021-149679

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Effect of GVHD prophylaxis on renal function and survival outcomes in allogeneic hematopoietic cell transplant patients with pre-existing renal impairment

Outcomes of elderly (≥ 70) Acute Myeloid Leukemia (AML) patients receiving continued hypomethylating agent/venetoclax (HMA/VEN) versus allogeneic hematopoietic cell transplantation (HCT)

Rare cancer, rare survivors: A 20-year single-center review of adult T-cell lymphoma/leukemia treatment outcomes

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Impact of pre-existing psychiatric conditions on toxicity and outcomes of patients after BCMA-directed CAR-T cell therapy

Infections in patients with relapsed refractory multiple myeloma receiving idecabtagene vicleucel therapy: A real-world analysis from CIBMTR

Refined elderly comorbidity index is highly predictive of post-transplant survival in older adults with Acute Myeloid Leukemia and myelodysplastic syndrome

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Impact of pre-existing central nervous system conditions and cognitive impairments on toxicity and outcomes after BCMA-directed CAR-T cell therapy

Impact of autoimmune disease on outcomes after BCMA-directed CAR-T cell therapy for patients with multiple myeloma

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Impact of Neurological and Psychiatric Comorbidities on Toxicity and Outcomes of Patients with DLBCL Who Receive Axicabtagene Ciloleucel

Impact of Autoimmune Disease on Toxicity and Outcomes after Axicabtagene Ciloleucel in Patients with Diffuse Large B Cell Lymphoma

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

CD25 As Feedback Regulator of Oncogenic TCR Signaling in T-Cell Lymphoma

Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only